检验医学与临床
檢驗醫學與臨床
검험의학여림상
JOURNAL OF LABORATORY MEDICINE AND CLINICAL SCIENCES
2014年
2期
183-185
,共3页
肺癌%癌胚抗原%糖类抗原50%细胞角质蛋白%鳞状细胞癌抗原%神经烯醇化酶
肺癌%癌胚抗原%糖類抗原50%細胞角質蛋白%鱗狀細胞癌抗原%神經烯醇化酶
폐암%암배항원%당류항원50%세포각질단백%린상세포암항원%신경희순화매
lung caner%CEA%NSE%CYFRA21-1%CA50%SCC
目的：探讨血清癌胚抗原（CEA）、糖类抗原50（CA50）、细胞角质蛋白（CYFRA21-1）、鳞状细胞癌抗原（SCC）和神经烯醇化酶（NSE）对晚期肺癌化疗疗效及进展评估的意义。方法分别采取2008～2012年确诊的肺癌（Ⅲ b ～Ⅳ期）患者的化疗前、缓解及进展时的血清标本，检测每份血清标本 CEA 、CA50、CYFRA21-1、SCC 和NSE 5种肿瘤标记物，比较它们之间的差异及探讨其与不同病理类型的晚期肺癌化疗疗效的关系。结果综合考虑疗效与病理类型两方面影响因素，CEA 、CA50、CYFRA21-1、SCC 和 NSE 的数值变化差异均有统计学意义（PCEA＝0．034、PCA50＝0．003、PCYFRA21-1＝0．039、PSCC ＝0．019和 PNSE ＝0．000），且 CEA 及 CA50数值变化在肺腺癌组最为明显，CYFRA21-1及 SCC 数值变化在肺鳞癌组最为明显，NSE 数值变化在肺小细胞癌组最为明显。结论肿瘤标志物 CEA 、CA50、CYFRA21-1、SCC 和 NSE 可分别作为晚期肺腺癌、鳞癌及小细胞癌的化疗疗效及进展评估的重要指标。
目的：探討血清癌胚抗原（CEA）、糖類抗原50（CA50）、細胞角質蛋白（CYFRA21-1）、鱗狀細胞癌抗原（SCC）和神經烯醇化酶（NSE）對晚期肺癌化療療效及進展評估的意義。方法分彆採取2008～2012年確診的肺癌（Ⅲ b ～Ⅳ期）患者的化療前、緩解及進展時的血清標本，檢測每份血清標本 CEA 、CA50、CYFRA21-1、SCC 和NSE 5種腫瘤標記物，比較它們之間的差異及探討其與不同病理類型的晚期肺癌化療療效的關繫。結果綜閤攷慮療效與病理類型兩方麵影響因素，CEA 、CA50、CYFRA21-1、SCC 和 NSE 的數值變化差異均有統計學意義（PCEA＝0．034、PCA50＝0．003、PCYFRA21-1＝0．039、PSCC ＝0．019和 PNSE ＝0．000），且 CEA 及 CA50數值變化在肺腺癌組最為明顯，CYFRA21-1及 SCC 數值變化在肺鱗癌組最為明顯，NSE 數值變化在肺小細胞癌組最為明顯。結論腫瘤標誌物 CEA 、CA50、CYFRA21-1、SCC 和 NSE 可分彆作為晚期肺腺癌、鱗癌及小細胞癌的化療療效及進展評估的重要指標。
목적：탐토혈청암배항원（CEA）、당류항원50（CA50）、세포각질단백（CYFRA21-1）、린상세포암항원（SCC）화신경희순화매（NSE）대만기폐암화료료효급진전평고적의의。방법분별채취2008～2012년학진적폐암（Ⅲ b ～Ⅳ기）환자적화료전、완해급진전시적혈청표본，검측매빈혈청표본 CEA 、CA50、CYFRA21-1、SCC 화NSE 5충종류표기물，비교타문지간적차이급탐토기여불동병리류형적만기폐암화료료효적관계。결과종합고필료효여병리류형량방면영향인소，CEA 、CA50、CYFRA21-1、SCC 화 NSE 적수치변화차이균유통계학의의（PCEA＝0．034、PCA50＝0．003、PCYFRA21-1＝0．039、PSCC ＝0．019화 PNSE ＝0．000），차 CEA 급 CA50수치변화재폐선암조최위명현，CYFRA21-1급 SCC 수치변화재폐린암조최위명현，NSE 수치변화재폐소세포암조최위명현。결론종류표지물 CEA 、CA50、CYFRA21-1、SCC 화 NSE 가분별작위만기폐선암、린암급소세포암적화료료효급진전평고적중요지표。
Objective To investigate the significance of cancer embryonic antigen (CEA) ,carbohydrate antigen 50(CA50) ,cytokaratin(CYFRA21-1) ,squamous cell cancer antigen(SCC) and neuron specific enolase(NSE) on the chemotherapy efficacy and the progress evaluation in advanced lung cancer .Methods The serum samples were col-lected before chemotherapy ,in remission and progression from the patients diagnosed with advanced lung cancer (IIIb-IV) during 2008-2012 .Each sample was detected the five tumor markers CEA ,CA50 ,CYFRA21-1 ,SCC and NSE . The differences among them were compared and their relationship with chemotherapy efficacy in different pathologi -cal types of advanced lung cancer was investigated .Results Considering the influencing factors of efficacy and patho-logical types ,the differences of CEA ,CA50 ,CYFRA21-1 ,SCC and NSE values had statistical significance (PCEA =0 .034 ,PCA50 = 0 .003 ,PCYFRA21-1 = 0 .039 ,PSCC = 0 .019 and PNSE = 0 .000) .The changes of CEA and CA50 values were most obvious in the lung adenocarcinoma group ,which of CYFRA21-1 and SCC value were most evident in the lung squamous cell carcinoma group and which of NSE value were most pronounced in the small cell carcinoma of lung group .Conclusion The tumor markers of CEA ,CA50 ,CYFRA21-1 ,SCC and NSE could be used as the important in-dicators for the evaluation of chemotherapy efficacy and progress in advanced lung adenocarcinoma ,squamous cell carcinoma and small cell carcinoma .
